The heterozygous NUDT15 variant is not associated with the severity of 6-mercaptopurine-related side effects in early intensification therapy for childhood acute lymphoblastic leukemia

Background: In the treatment of childhood acute lymphoblastic leukemia (ALL), 6-mercaptopurine (6-MP) is essential for early intensification and maintenance of therapy. Recently, an association between genetic variants of nudix hydrolase 15 (NUDT15) rs116855232 and 6-MP-induced severe myelotoxicity...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jimei Zhao, Masahiro Ueki, Saori Sawai, Minako Sugiyama, Yukayo Terashita, Shinsuke Hirabayashi, Yuko Cho, Ryoji Kobayashi, Yoichi Tanaka, Atsushi Manabe
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2023-01-01
Col·lecció:	EJC Paediatric Oncology
Matèries:	Leukemia Children NUDT15 Mercaptopurine Side effects
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2772610X23000041
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!